Avondale Upgrades Amedisys (AMED) to Market Perform
Tweet
Share
E-mailGet Alerts AMED Hot Sheet
Price: $100.99 --0%
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 54
Rating Summary:
6 Buy, 15 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 8 | New: 54
Join SI Premium – FREE
Avondale Partners upgraded shares of Amedisys (NASDAQ: AMED) from Market Underperform to Market Perform Wednesday morning. The firm's price target was raised from $9.50 to $10.50.
The stock is outperforming this afternoon. Shares last traded at $10.45, up about 1.5 percent.
For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.
The stock is outperforming this afternoon. Shares last traded at $10.45, up about 1.5 percent.
For an analyst ratings summary and ratings history on Amedisys click here. For more ratings news on Amedisys click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Barclays Upgrades United Internet AG (UTDI:GR) (UDIRY) to Overweight
- JPMorgan Upgrades Japan Post Insurance Co., Ltd (7181:JP) (JPPIF) to Overweight
- Barclays Upgrades 1&1 AG (1U1:GR) to Overweight
Create E-mail Alert Related Categories
UpgradesRelated Entities
Avondale PartnersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
